NIKKEI 225
38,471.20 -761.60 (-1.94%) HANG SENG
16,248.97 -351.49 (-2.12%) CRUDE OIL
85.20 -0.21 (-0.25%) GOLD FUTURES
2,403.20 +20.20 (+0.85%) DOW
37,847.65 +112.54 (+0.30%) Bitcoin GBP
50,620.92 -777.28 (-1.51%)
Astellas Pharma Inc. (ALPMF)
Astellas Pharma Inc.
2-5-1, Nihonbashi-Honcho
Chuo-Ku
Tokyo 103-8411
Japan
81 3 3244 3000
https://www.astellas.com
Sector(s): Healthcare
Industry: Drug Manufacturers - General
Full-time employees: 14,484
Key executives
| Name | Title | Pay | Exercised | Year born |
|---|---|---|---|---|
| Mr. Naoki Okamura BSc | President, CEO & Director | 952.07k | N/A | 1962 |
| Mr. Atsushi Kitamura | Chief Financial Officer | N/A | N/A | N/A |
| Nobue Yasuda | General Manager of Finance & Accounting Department | N/A | N/A | N/A |
| Mr. Yoshitsugu Shitaka Ph.D. | Chief Scientific Officer & Senior Managing Executive Officer | N/A | N/A | N/A |
| Ms. Catherine B. Levitt | General Counsel | N/A | N/A | N/A |
| Mr. Katsuyoshi Sugita | Chief People Officer, Chief Ethics & Compliance Officer, EVP of HR and Representative Director | N/A | N/A | 1967 |
| Mr. Stig Ogata | Vice President of Corporate Communications | N/A | N/A | N/A |
| Ms. Collette Taylor | Senior Vice President of Human Resources | N/A | N/A | 1963 |
| Ms. Tatjana Dragovic | Senior VP and Head of Ethics & Compliance | N/A | N/A | N/A |
| Mr. Nobuaki Tanaka | President of Japan Commercial & Senior Corporate Executive | N/A | N/A | N/A |
Description
Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. Th company has a research collaboration with Vivtex Corporation to evaluate Vivtex's GI-ORIS screening and formulation platform technology to support the development of novel and oral versions of a therapeutic candidate provided by Astellas; and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution. The company was founded in 1923 and is headquartered in Tokyo, Japan.
Corporate governance
Astellas Pharma Inc.’s ISS governance QualityScore as of 1 April 2024 is 2. The pillar scores are Audit: 1; Board: 2; Shareholder rights: 6; Compensation: 1.
